At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 104 enrolled
Drug / intervention
Travoprost 0.004% ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma
In Brief
A Phase 4 clinical trial evaluating Travoprost 0.004% ophthalmic solution and Bimatoprost 0.01% ophthalmic solution for Glaucoma and Ocular Hypertension. Completed, enrolled 104 participants.
Detailed Summary
The purpose of this study is evaluate effects of TRAVATAN® versus LUMIGAN® on intraocular pressure (IOP) and ocular surface and inflammatory biomarkers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartSep 2012
Primary CompletionJun 2014
TodayJul 2026
First PostedAug 14, 2012
Enrollment StartSep 1, 2012
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.9 years ago
Interventions
Travoprost 0.004% ophthalmic solutiondrug
Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
Bimatoprost 0.01% ophthalmic solutiondrug
Ophthalmic solution containing benzalkonium chloride (BAK)